Has Steven Finkelstein, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,610,169 in general payments to Steven Finkelstein, MD across 974 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Steven Finkelstein, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Steven Finkelstein, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Steven Finkelstein, MD

Radiation Oncology · Syracuse, NYNPI 1700078409

Payments from drug & device makers

$2,610,169in general payments, 2019–2025

Across 974 payments — averaging $2679.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$2.1M
Progenics Pharmaceuticals, Inc.$146K
Bayer$139K
Johnson & Johnson$72K
AstraZeneca$35K
Astellas Pharma US Inc$28K
plus $123K from 54 others

What the payments were for

Consulting fees$204,35035%
Speaking & faculty fees$303,16352%
Travel & lodging$49,1849%
Food & beverage$21,2404%
Education$940%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	107	$2,066,474
Progenics Pharmaceuticals, Inc.	55	$145,544
Bayer	133	$138,876
Johnson & Johnson(2 entities)	135	$71,885
AstraZeneca(2 entities)	52	$34,825
Astellas Pharma US Inc	42	$28,388
Blue Earth Diagnostics	20	$26,293
Bioprotect Medical, Inc.	16	$25,019
Tolmar, Inc.	2	$15,240
Pfizer	24	$11,200
Sumitomo Pharma America, Inc.	4	$10,912
Boston Scientific	9	$9,886
Janssen Scientific Affairs, LLC	7	$4,076
Novocure Inc.	6	$2,748
Amgen	34	$2,534
Myovant Sciences Inc.	4	$2,238
E.r. Squibb & Sons, L.L.C.	23	$1,928
Janssen Global Services, LLC	1	$1,755
Taiho Oncology, Inc.	3	$1,743
Regeneron Healthcare Solutions, Inc.	30	$850
Elekta, Inc.	5	$580
Siemens Medical Solutions USA, Inc.	4	$506
Daiichi Sankyo Inc.	8	$505
Eisai Inc.	24	$409
Athenex Pharmaceutical Division, LLC	4	$376
Ferring Pharmaceuticals Inc.	7	$356
Sanofi	17	$340
Octapharma USA, Inc.	3	$304
Merck	14	$276
Dendreon Pharmaceuticals LLC	8	$274
Lilly USA, LLC	12	$197
Myriad Genetic Laboratories, Inc.	3	$191
Beigene USA, Inc.	11	$181
Foundation Medicine, Inc.	3	$170
Telix Pharmaceuticals	4	$151
AbbVie	7	$150
Incyte Corporation	8	$148
Histosonics, Inc.	1	$142
Teleflex LLC	2	$138
Takeda Pharmaceuticals U.S.A., Inc.	6	$132
Bristol Myers Squibb	7	$104
Pharmacosmos Therapeutics Inc.	4	$101
Coherus Oncology, Inc.	5	$93
Genentech USA, Inc.	2	$89
Boehringer Ingelheim	4	$88
Seagen Inc.	5	$84
Blueprint Medicines Corporation	4	$83
Accord Healthcare, Inc.	4	$82
CSL Behring	3	$81
GSK	5	$79
G1 Therapeutics, Inc.	4	$77
Immunitybio, Inc.	2	$74
Springworks Therapeutics, Inc.	4	$71
Ipsen Biopharmaceuticals, Inc	3	$70
Exelixis Inc.	4	$70
Jazz Pharmaceuticals Inc.	3	$70
AVEO Pharmaceuticals, Inc.	3	$63
Karyopharm Therapeutics Inc.	3	$52
Rigel Pharmaceuticals, Inc.	3	$50
Mirati Therapeutics, Inc.	3	$49

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

PYLARIFY$145,132
Xofigo$108,311
Erleada$73,926
XTANDI$35,737
Nubeqa$31,965
IMFINZI$28,655
BIOPROTECT BALLOON IMPLANT SYSTEM$24,795
PLUVICTO$17,366
Axumin$15,631
ELIGARD$13,440
ORGOVYX$13,426
POSLUMA$8,456
SPACEOAR$5,000
GENERAL BPH$4,400
BAVENCIO$2,657
Oncology$2,500
ZYTIGA$1,755
Lonsurf$1,713
TAGRISSO$1,510
Versa HD$361

How this compares

$2,610,169 in reported general payments places this provider in the 95th percentile of 397 radiation oncology providers in New York.

See all radiation oncology providers in New York →

Medicare billing

Part B allowed, 2024

$881,987

Medicare patients

248

Services billed

3,935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other radiation oncology in Syracuse

Chung ChungSyracuse$3.1M
Jeffrey BogartSyracuse$836K
Michael MixSyracuse$227K
Narek ShaverdianNew York$9.8M
Timothy ChanNew York$3.8M
Brandon ImberNew York$2.8M
Silvia FormentiNew York$2.7M
Christopher BarkerNew York$2.5M
Chandan GuhaBronx$1.6M
Michael ZelefskyNew York$1.5M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →